The 2021 Philips CPAP recall — one of the largest in medical device history — exposed millions of users to carcinogenic foam particles and VOCs. Cancers linked to exposure include nasopharyngeal, lung, kidney, liver, and bladder cancer. MDL 3014 in Pittsburgh is advancing toward bellwether trials in 2026.
Litigation Timeline
Philips Receives Internal Foam Degradation Complaints
Internal Philips Respironics documents indicate the company began receiving complaints about PE-PUR foam degradation in CPAP devices as early as 2015. Despite these early warning signs, Philips took no corrective action for approximately six years — a central allegation in the MDL litigation establishing corporate negligence.
Philips Issues Voluntary Recall — 15 Million Devices Affected
Philips Respironics issued a voluntary recall of approximately 15 to 16 million CPAP, BiPAP, and mechanical ventilator devices worldwide (approximately 5.5 million U.S. units). The recall cited PE-PUR foam degradation as a potential health risk, including release of VOCs and particulate matter into the breathing pathway. The affected model range spans 2009–2021, including the DreamStation, System One, REMstar, and other product lines.
FDA Elevates to Class I Recall — Highest Severity
The FDA classified the Philips CPAP recall as a Class I recall — its most serious category, indicating a reasonable probability that use of the recalled devices will cause serious adverse health consequences or death. FDA testing subsequently identified over 200 chemical compounds in degraded PE-PUR foam, including known and suspected human carcinogens such as toluene diisocyanate and dimethylformamide.
MDL 3014 Formed in Western District of Pennsylvania
The Judicial Panel on Multidistrict Litigation (JPML) consolidated Philips CPAP personal injury cases into MDL 3014 in the U.S. District Court for the Western District of Pennsylvania in Pittsburgh. Chief Judge Joy Flowers Conti was assigned to preside over the litigation, which is headquartered in Philips Respironics's home district. MDL 3014 docket: 2:21-mc-01230-JFC.
Philips Reserves $1.1 Billion — Daubert Battles Intensify
Philips N.V. disclosed approximately $1.05–1.1 billion USD in litigation reserves in its 2024 annual report. The MDL entered a critical phase of general causation expert discovery and Daubert motion practice, with Philips aggressively challenging plaintiffs' expert testimony on the causal link between foam VOC exposure and specific cancers. Bellwether trial pools were identified for a 2026 trial schedule.
Bellwether Trials Targeting 2026 — Settlement Pressure Building
As of early 2026, MDL 3014 has over 100,000 personal injury cases filed and is advancing toward bellwether trials on a 2026 schedule. No global settlement has been announced, but market analysts estimate total Philips liability exposure at $4–6 billion. Philips's $1.1 billion reserve is widely viewed as insufficient if bellwether verdicts go unfavorably, creating significant pressure for a global resolution similar to the 3M earplug MDL's $6 billion settlement.
Get free updates on the CPAP Cancer as it develops
No phone call required. We will email you when there is meaningful news — new filings, settlements, or important deadlines.
Want the Complete Picture?
View eligibility criteria, settlement information, scientific evidence, and start a free case review.
View Full CPAP Cancer Case Page